MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/jcm14207294

Медицинская библиотека · Journal of clinical medicine · 2025

Real-World Outcomes of Antifungal Prophylaxis in Adult Acute Lymphoblastic Leukemia Patients: A Multicenter Comparison of the Use of Fluconazole and Micafungin.

Atas Unal, Iltar Utku, Yucel Orhan Kemal, Salur Hasan, Bilek Merve Cagla, Ustabas Tayfun, Candan Ozlem, Korkmaz Gulten, Kucukyurt Selin, Tiglioglu Pinar, Yigit Kaya Sureyya, Deveci Burak, Tekinalp Atakan, Ciftciler Rafiye, Senturk Yikilmaz Aysun, Elibol Tayfun, Toptas Tayfur, Gunes Ahmet Kursad, Sevindik Omur Gokmen, Kaynar Leylagul, Saba Rabin, Atagunduz Isik, Ozet Gulsum, Karakus Volkan, Salim Ozan, Kurtoglu Erdal, Undar Levent

СтатьяПеревод пока не подготовлен

Аннотация

Background

Adult acute lymphoblastic leukemia (ALL) patients are at increased risk of invasive fungal infections (IFIs) due to intensive therapy and prolonged neutropenia. While pediatric guidelines support administering fluconazole or mold-active agents, the evidence in adults is limited. This study presents the first multicenter retrospective comparison of fluconazole and micafungin use in this setting.

Methods

We retrospectively analyzed 336 adult ALL patients from 11 centers in Türkiye (2010-2024) who received fluconazole (n = 230) or micafungin (n = 106) during induction chemotherapy. IFIs were classified according to the EORTC/MSG criteria.

Results

The median age was 38.5 years, and 38.7% were female. Proven/probable IFIs occurred in 8.9% of patients, with similar rates between the fluconazole and micafungin groups (8.7% vs. 9.4%; p = 0.82). Multivariate analysis confirmed no significant association between the prophylactic antifungal type and IFI incidence, indicating comparable outcomes across groups. The median prophylaxis duration was longer with fluconazole, while the discontinuation rates, switch patterns, and subsequent antifungal use were comparable. The overall infection rates (~60%) and distribution of bacterial, viral, and polymicrobial infections were similar between the two groups. Prior bacterial infection increased the risk of IFI by 2.7-fold, and IFI-positive patients had longer neutropenia. At the end of induction, the remission, refractory, and mortality rates were similar between groups. The median overall survival was 24 months.

Conclusions

Fluconazole and micafungin showed similar efficacy as the primary antifungal prophylaxis treatment in adult ALL patients. Given the limited evidence in adults and the ongoing need to optimize antifungal strategies, prospective randomized trials directly comparing these agents in this population are needed to confirm and expand upon our findings.

Для цитирования: Atas Unal, Iltar Utku, Yucel Orhan Kemal, Salur Hasan, Bilek Merve Cagla, Ustabas Tayfun, Candan Ozlem, Korkmaz Gulten, Kucukyurt Selin, Tiglioglu Pinar, Yigit Kaya Sureyya, Deveci Burak, Tekinalp Atakan, Ciftciler Rafiye, Senturk Yikilmaz Aysun, Elibol Tayfun, Toptas Tayfur, Gunes Ahmet Kursad, Sevindik Omur Gokmen, Kaynar Leylagul, Saba Rabin, Atagunduz Isik, Ozet Gulsum, Karakus Volkan, Salim Ozan, Kurtoglu Erdal, Undar Levent. Real-World Outcomes of Antifungal Prophylaxis in Adult Acute Lymphoblastic Leukemia Patients: A Multicenter Comparison of the Use of Fluconazole and Micafungin.. Journal of clinical medicine. 2025. DOI: 10.3390/jcm14207294.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.